氢化可的松联合氟氢可的松治疗成人脓毒性休克
APROCCHSS 多中心双盲随机试验,原为2×2析因设计,评估氢化可的松联合氟氢可的松、drotrecogin alfa(活化)及三者联用或各自安慰剂;drotrecogin alfa(活化)撤市后改为两组平行设计,比较氢化可的松联合氟氢可的松组与安慰剂组。共纳入1241例脓毒性休克患者,90天全因死亡率联合组43.0%(264/614)vs 安慰剂组49.1%(308/627),P=0.03,RR 0.88(95%CI 0.78–0.99)。ICU出院、出院时及180天死亡率联合组均显著低于安慰剂组,28天死亡率两组无显著差异;联合组28天内无升压药天数和无器官衰竭天数显著更多,无机械通气天数两组相似;严重不良事件率两组无显著差异,但高血糖在联合组更常见。
要点
- 脓毒性休克成人中,氢化可的松联合氟氢可的松组90天全因死亡率43.0%(264/614)vs 安慰剂组49.1%(308/627),P=0.03,RR 0.88(95%CI 0.78–0.99)。
- ICU出院死亡率联合组35.4% vs 安慰剂组41.0%(P=0.04),出院时39.0% vs 45.3%(P=0.02),180天46.6% vs 52.5%(P=0.04);28天死亡率33.7% vs 38.9%(P=0.06)无显著差异。
- 28天内无升压药天数联合组17天 vs 安慰剂组15天(P<0.001),无器官衰竭天数14天 vs 12天(P=0.003),无机械通气天数11天 vs 10天(P=0.07)无显著差异。
- 严重不良事件率两组无显著差异,但高血糖在氢化可的松联合氟氢可的松组更常见。
适用人群与场景
- 脓毒性休克成人患者,共1241例纳入本试验。
研究设计与关键结果
- 多中心、双盲、随机试验,原为2×2析因设计,评估氢化可的松联合氟氢可的松、drotrecogin alfa(活化)、三者联用或各自安慰剂;drotrecogin alfa(活化)撤市后改为两组平行设计,比较氢化可的松联合氟氢可的松组与安慰剂组。
- 共1241例脓毒性休克患者;90天全因死亡率联合组43.0%(264/614)vs 安慰剂组49.1%(308/627),P=0.03,RR 0.88(95%CI 0.78–0.99)。
- ICU出院死亡率联合组35.4% vs 安慰剂组41.0%(P=0.04),出院时39.0% vs 45.3%(P=0.02),180天46.6% vs 52.5%(P=0.04);28天死亡率33.7% vs 38.9%(P=0.06),无显著差异。
- 28天内无升压药天数联合组17天 vs 安慰剂组15天(P<0.001);无器官衰竭天数14天 vs 12天(P=0.003);无机械通气天数11天 vs 10天(P=0.07),无显著差异。
- 严重不良事件率两组无显著差异,但高血糖在氢化可的松联合氟氢可的松组更常见。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机对照试验(APROCCHSS,ClinicalTrials.gov NCT00625209)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于脓毒性休克成人,本试验显示氢化可的松联合氟氢可的松较安慰剂降低90天全因死亡率(43.0% vs 49.1%,RR 0.88,95%CI 0.78–0.99),并降低ICU出院、出院时及180天死亡率,增加28天内无升压药天数和无器官衰竭天数。
- 使用氢化可的松联合氟氢可的松时需注意高血糖在该组更常见;严重不良事件率两组无显著差异。
指南或共识出处
- APROCCHSS试验,ClinicalTrials.gov NCT00625209,由法国社会事务与卫生部2007年临床研究医院项目资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock.
METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group).
RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group.
CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
参考来源
- Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018. PMID: 29490185. doi:10.1056/NEJMoa1705716
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。